Saturday, 24 February 2007

Aprotinin - more to worry about...

A new study from Managno's research group finds that five year mortality is increased in patients undergoing CABG who were treated with Aprotinin compared with other agents (aminocaproic acid and tranexamic acid). This adds further credibility to their study in the NEJM from last year. However, the methodology (observational study with statistical adjustment for patient variables) will probably still cause debate. Although Tranexamic acid is not marketed in Australia, Westmead will be making it available under the TGAs Special Access Scheme. Bayer, the makers of Aprotinin (Trasylol) have made their own response. Similar news last year lead to in a fall in the Bayer share price of 3%.

No comments:

Post a Comment